Pilot-program designed to screen for diabetic retinopathy in Costa Rica
Roche, Ainnova, and Salud 360 signed this alliance to improve access to vision screening in patients with uncontrolled diabetes.
(Image credit: AdobeStock/Sbastien)
Avant Technologies Inc.’s partner, Ainnova Tech, Inc., has entered a strategic alliance with global biotech, Roche, and pre-paid health plan provider, Salud 360, to begin a pilot program to combat diabetic retinopathy using Ainnova’s technology. The pilot program is set to be implemented in Costa Rica.1
If successful, Avant and Ainnova hope to implement a similar program in the United States, Canada, and Europe through Ai-nova Acquisition Corp. (AAC), the company formed by the partnership between Avant and Ainnova.1
Roche, Ainnova, and Salud 360 signed this alliance to improve access to vision screening in patients with uncontrolled diabetes with the hope of decreasing the risks of diabetic retinopathy using Ainnova’s advanced technology and a patient-centered approach. The pilot program will use non-mydriatic fundus cameras and artificial intelligence, developed by Ainnova Tech, to automatically analyze retinal images and identify microscopic changes in the retina. These changes could indicate diabetic retinopathy without the need for invasive tests.1
By implementing the program in Costa Rica, this alliance can use the advantage of the country's robust healthcare system and its focus on technological innovation. Patients who are members of Salud 360 will be the first to benefit from screenings at affiliated clinics. Those at risk will be referred immediately to ophthalmology specialists for comprehensive and timely care. The results of this program will be the basis for developing the model beyond our borders to benefit communities facing similar challenges in accessing medical care.1
